Oestrogen receptor status and survival in women with BRCA2-associated breast cancer.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
23
05
2018
accepted:
03
01
2019
revised:
06
12
2018
pubmed:
7
2
2019
medline:
31
10
2019
entrez:
7
2
2019
Statut:
ppublish
Résumé
To evaluate the predictors of mortality, including ER status, in women with a BRCA2 mutation and breast cancer. Eligible participants were identified from within two longitudinal cohorts. These patients were selected because they were diagnosed with breast cancer between 1975 and 2015 and carried a BRCA2 mutation. Data were abstracted from the medical record and pathology report. We analysed the effects of ER status and other variables on breast cancer specific survival using a Cox proportional hazards model. Three hundred ninety women with breast cancer and a BRCA2 mutation were included in the analysis. The mean follow-up time was 12.3 years (range 1-39 years) and 89 subjects died (22.8%). In the multivariate analysis, women with ER-positive tumours were more likely to die than women with ER-negative tumours (HR 2.08, 95% CI 0.99-4.36, p = 0.05), and this was of borderline significance. For the 233 women with ER-positive tumours the 20-year survival rate was 62.2%, compared to 83.7% for 58 women with ER-negative tumours (p = 0.03). The majority of women with a BRCA2 mutation present with ER-positive breast cancer, and for these women, prognosis may be worse than for BRCA2 carriers with ER-negative breast cancer.
Sections du résumé
BACKGROUND
To evaluate the predictors of mortality, including ER status, in women with a BRCA2 mutation and breast cancer.
METHODS
Eligible participants were identified from within two longitudinal cohorts. These patients were selected because they were diagnosed with breast cancer between 1975 and 2015 and carried a BRCA2 mutation. Data were abstracted from the medical record and pathology report. We analysed the effects of ER status and other variables on breast cancer specific survival using a Cox proportional hazards model.
RESULTS
Three hundred ninety women with breast cancer and a BRCA2 mutation were included in the analysis. The mean follow-up time was 12.3 years (range 1-39 years) and 89 subjects died (22.8%). In the multivariate analysis, women with ER-positive tumours were more likely to die than women with ER-negative tumours (HR 2.08, 95% CI 0.99-4.36, p = 0.05), and this was of borderline significance. For the 233 women with ER-positive tumours the 20-year survival rate was 62.2%, compared to 83.7% for 58 women with ER-negative tumours (p = 0.03).
CONCLUSIONS
The majority of women with a BRCA2 mutation present with ER-positive breast cancer, and for these women, prognosis may be worse than for BRCA2 carriers with ER-negative breast cancer.
Identifiants
pubmed: 30723304
doi: 10.1038/s41416-019-0376-y
pii: 10.1038/s41416-019-0376-y
pmc: PMC6462020
doi:
Substances chimiques
Receptors, Estrogen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
398-403Références
J Clin Oncol. 2010 Jan 20;28(3):375-9
pubmed: 20008645
Cancer. 2016 Apr 15;122(8):1178-84
pubmed: 26859126
Breast Cancer Res Treat. 2017 Sep;165(2):391-402
pubmed: 28601929
J Clin Oncol. 2016 Jul 1;34(19):2232-8
pubmed: 27161974
Breast Cancer Res. 2012 Jul 20;14(4):R110
pubmed: 22817698
Br J Cancer. 2016 Sep 27;115(7):776-83
pubmed: 27537391
Int J Cancer. 2017 May 1;140(9):2145-2149
pubmed: 28120435
Breast Cancer Res Treat. 2016 Jun;157(3):511-6
pubmed: 27225387
N Engl J Med. 2007 Jul 12;357(2):115-23
pubmed: 17625123
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
J Clin Oncol. 2012 Jan 1;30(1):19-26
pubmed: 22147742
J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
pubmed: 9747868
Breast Cancer Res Treat. 2014 Sep;147(2):401-5
pubmed: 25129345
Cancer. 2005 Jun 1;103(11):2241-51
pubmed: 15844176
Cancer. 1984 Nov 15;54(10):2237-42
pubmed: 6488142
Eur J Cancer. 2007 Mar;43(5):867-76
pubmed: 17307353
J Natl Cancer Inst. 2016 Sep 06;109(1):
pubmed: 27601060
Breast Cancer Res Treat. 2009 May;115(2):359-63
pubmed: 18649131
JAMA Oncol. 2015 Jun;1(3):306-13
pubmed: 26181175
Lancet Oncol. 2018 Feb;19(2):169-180
pubmed: 29337092
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47
pubmed: 22144499
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
Surg Gynecol Obstet. 1991 Oct;173(4):273-8
pubmed: 1925896